NCT05246878View on ClinicalTrials.gov

A Study of EDP-235 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 28, 2022

Primary Completion Date

July 20, 2022

Study Completion Date

July 20, 2022

Conditions
SARS CoV 2 Infection
Interventions
DRUG

EDP-235

Oral administration

DRUG

Placebo

Placebo to match EDP-235, oral administration

Trial Locations (1)

66219

Pharmaceutical Research Associates, Inc.,, Lenexa

Sponsors
All Listed Sponsors
lead

Enanta Pharmaceuticals, Inc

INDUSTRY

NCT05246878 - A Study of EDP-235 in Healthy Subjects | Biotech Hunter | Biotech Hunter